Gastrointestinal Tract Colonization With Fluoroquinolone-Resistant Escherichia coli in Hospitalized Patients: Changes Over Time in Risk Factors for Resistance

Division of Infectious Diseases, Department of Medicine, the Center for Clinical Epidemiology and Biostatistics, the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6021, USA.
Infection Control and Hospital Epidemiology (Impact Factor: 4.18). 01/2009; 30(1):18-24. DOI: 10.1086/592703
Source: PubMed


The prevalence of fluoroquinolone (FQ) resistance in Escherichia coli has increased markedly in recent years. Despite the important role of gastrointestinal tract colonization with FQ-resistant E. coli (FQREC), the prevalence of and risk factors for FQREC colonization among the general hospitalized patient population have not been described, to our knowledge. The objective of this study was to identify the prevalence of and risk factors for FQREC colonization among hospitalized patients.
Three-year case-control study. Case patients (ie, all subjects with FQREC colonization) were compared with control patients (ie, all subjects without FQREC colonization).
Two large medical centers within an academic health system.
All patients hospitalized at the 2 study hospitals.
Three annual fecal surveillance surveys were conducted. All patients colonized with FQREC (levofloxacin minimum inhibitory concentration, >or=8 microg/mL) were identified.
Of the 774 subjects, 89 (11.5%) were colonized with FQREC. Although there was a significant association between prior FQ use and FQREC colonization on bivariable analysis (odds ratio [OR], 2.02 [95% confidence interval {CI}, 1.14-3.46]; P=.01), there was statistically significant effect modification by year of study (P=.005). In multivariable analyses, after controlling for the hospital and for the duration of hospitalization prior to sampling, the association between FQ use and FQREC colonization was as follows: adjusted OR (aOR), 0.97 (95% CI, 0.29-3.23) in 2002; aOR, 1.41 (95% CI, 0.57-3.50) in 2003; and aOR, 9.87 (95% CI, 3.67-26.55) in 2004.
The association between prior FQ use and FQREC colonization varied significantly by study year, suggesting that the clinical epidemiology of resistant organisms may change over time. Furthermore, in the context of recent work showing significant changes in FQREC prevalence as well as changes in FQ resistance mechanisms (specifically, efflux overexpression) over the same time period, these results suggest a previously unrecognized complexity in the relationship between the clinical and molecular epidemiology of FQ resistance.

Download full-text


Available from: Pam Tolomeo, Mar 31, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Drug efflux pumps play a key role in drug resistance and also serve other functions in bacteria. There has been a growing list of multidrug and drug-specific efflux pumps characterized from bacteria of human, animal, plant and environmental origins. These pumps are mostly encoded on the chromosome, although they can also be plasmid-encoded. A previous article in this journal provided a comprehensive review regarding efflux-mediated drug resistance in bacteria. In the past 5 years, significant progress has been achieved in further understanding of drug resistance-related efflux transporters and this review focuses on the latest studies in this field since 2003. This has been demonstrated in multiple aspects that include but are not limited to: further molecular and biochemical characterization of the known drug efflux pumps and identification of novel drug efflux pumps; structural elucidation of the transport mechanisms of drug transporters; regulatory mechanisms of drug efflux pumps; determining the role of the drug efflux pumps in other functions such as stress responses, virulence and cell communication; and development of efflux pump inhibitors. Overall, the multifaceted implications of drug efflux transporters warrant novel strategies to combat multidrug resistance in bacteria.
    Full-text · Article · Feb 2009 · Drugs
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review explores recent evidence on the association between antibiotics usage and resistance. A meta-analysis showed that the risk of acquiring methicillin-resistant Staphylococcus aureus was increased by 1.8-fold in patients who had taken antibiotics. Such risk was almost three-times greater after using quinolones or glycopeptides. Significant heterogeneity between studies was mainly related to study designs. A Cochrane systematic review suggested that, although the quality of the evidence was poor, interventions to improve hospital antibiotic prescribing were associated with a reduction in the incidence of antimicrobial resistant pathogens. Against this evidence, mupirocin-resistant S. aureus and linezolid-resistant vancomycin-resistant enterococci (VRE) were detected in institutions where these drugs were not widely used. Studies assessing the impact of vancomycin prescribing restriction on VRE rates were heterogeneous and the effectiveness of such interventions remains poorly defined. Important confounders of studies, other than study design, are the lack of analysis of secular trends of infections, colonization pressure in the ward and duration of follow up. Available evidence, although not always of high quality, suggests that a link between antibiotics usage at individual and institutional levels and resistant bacteria does exist. Benchmark guidelines for empiric therapy in hospitalized patients, taking into consideration not only patients' needs but also ecological costs of resistance, should be rapidly developed.
    Preview · Article · Jun 2009 · Current Opinion in Infectious Diseases
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Study for Monitoring Antimicrobial Resistance Trends (SMART) was intended to reveal the evolving profiles of antimicrobial resistance among Gram-negative pathogens causing intra-abdominal infections (IAIs). Aerobic and facultatively anaerobic Gram-negative isolates were prospectively collected from patients with IAIs in the Asia/Pacific region between 2002 and 2006. Only clinically significant isolates were included for susceptibility tests by the microdilution method. Phenotypic identification of extended-spectrum beta-lactamase (ESBL) production was performed on Escherichia coli, Klebsiella spp. and Enterobacter spp., with the measurements of MICs of cefepime alone and in the presence of clavulanic acid. Of 7239 Gram-negative isolates, Enterobacteriaceae accounted for the majority (81.5%), and the three major species were E. coli (42.5%), Klebsiella pneumoniae (15.7%) and Pseudomonas aeruginosa (9.6%). The susceptibility rates of Enterobacteriaceae isolates to cephalosporins decreased, in parallel with the fact that the prevalence of ESBLs increased from 13% in 2002 to 28% in 2006. Among E. coli isolates, the proportion of isolates producing an ESBL varied greatly between countries, ranging from 38.6% in China to 1.2% in New Zealand, and ciprofloxacin susceptibility rate from 41.6% in China to 95.8% in New Zealand. Carbapenems and amikacin were in vitro active against more than 95% of Enterobacteriaceae isolates. Antimicrobial resistance was frequently present among Gram-negative isolates from IAIs in the Asia/Pacific region. During the study period, there were increasing resistant rates of E. coli isolates to cephalosporins, but wide variations existed among countries. Regular updates of treatment guidelines for this region are necessary for empiric antimicrobial therapy.
    Full-text · Article · Jul 2009 · The Journal of infection
Show more